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OBJECTIVEdSpeciﬁc autoantibodies characterize type 1 diabetes in childhood but are also
found in adult-onset diabetes, even when initially non–insulin requiring, e.g., with latent auto-
immune diabetes (LADA). We aimed to characterize adult-onset autoimmune diabetes.
RESEARCH DESIGN AND METHODSdWe consecutively studied 6,156 European
diabetic patients attending clinics within 5 years of diagnosis (age range, 30–70 years) exam-
ined cross-sectionally clinically and for GAD antibodies (GADA) and antibodies to insulinoma-
associated antigen-2 (IA-2A) and zinc-transporter 8 (ZnT8A).
RESULTSdOf 6,156 patients, 541 (8.8%) had GADA and only 57 (0.9%) IA-2A or ZnT8A
alone. More autoantibody-positive than autoantibody-negative patients were younger, leaner, on
insulin (49.5 vs. 13.2%), and female (P, 0.0001 for each), though LADA patients (9.7% of total)
did not show categorically distinct clinical features from autoantibody-negative type 2 diabetes.
Similarly, more GADA patients with high (.200 World Health Organization IU) (n = 403)
compared with low (n = 138) titer were female, lean, and insulin treated (54.6 vs. 39.7%)
(P , 0.02 for each). Autoantibody-positive patients usually had GADA (541 of 598; 90.5%)
and had LADA more often than type 1 autoimmune diabetes (odds ratio 3.3).
CONCLUSIONSdAdult-onset autoimmune diabetes emerges as a prevalent form of autoim-
mune diabetes. Our results indicate that adult-onset autoimmune diabetes in Europe encompasses
type 1 diabetes and LADA in the same broad clinical and autoantibody-positive spectrum. At
diagnosis, patients with adult-onset autoimmune diabetes are usually non–insulin requiring and
clinically indistinguishable from patients with type 2 diabetes, though they tend to be younger and
leaner.Onlywith screening for autoantibodies, especiallyGADA, can they be identiﬁedwith certainty.
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Type 1 diabetes is an autoimmunedisease in which insulin deﬁciencyresults from immune-mediated de-
struction of insulin-secreting islet cells
(1). Type 1 diabetes was formerly called
insulin-dependent diabetes, reﬂecting the
severity of the destructive process and the
requirement for insulin therapy in all ca-
ses. The majority of patients with type 1
diabetes have autoantibodies in their pe-
ripheral blood, and these autoantibodies
can predict the future onset of the disease
(1). Autoimmune diabetes is character-
ized by speciﬁc autoantibodies such as
GAD autoantibodies (GADA), insuli-
noma-associated antigen-2 autoanti-
bodies (IA-2A) or zinc-transporter 8
autoantibodies (ZnT8A). Type 1 diabetes
is the most prevalent form of diabetes in
children but also occurs in adults (1). A
proportion of patients with adult-onset
initially non–insulin-requiring diabetes
have diabetes-associated autoantibodies
and are thought to have a form of auto-
immune diabetes called latent autoim-
mune diabetes of adult onset (LADA)
(2,3). Descriptions of the proportions of
LADA patients in clinical case series vary,
in part through selection biases such as
ascertainment of nonobese cases (4), in-
sulin-naïve cases (5), or treatment-naïve
cases (6) or the inclusion of impaired glu-
cose tolerance (7). These studies have es-
tablished that patients with autoimmune
diabetes, as characterized by the presence
of GADAs, have a clinical phenotype dis-
tinct from initially non–insulin-requiring
diabetic patients without GADAs who
are mostly designated as type 2 diabetic
(1–9). There are no studies of the relative
frequency of type 1 diabetes and LADA in
adults.
The key uncertainty regarding adult-
onset diabetic patients is whether LADA is
distinct from type 1 diabetes or more
common (10,11). Furthermore, it is as yet
unclear which factors are associated with
progression toward insulin therapy in
adult-onset autoimmune diabetes. Action
LADA is a European study that seeks to
address these questions by ascertaining
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adult-onset diabetic patients presenting
to nine European hospital-based clinics
(some recruiting from a community of
primary care settings; see below)
within a deﬁned period.We hypothesized
that autoimmune diabetes would be prev-
alent in Europe, that LADA would be
more prevalent than type 1 diabetes,
and that these two would show pheno-
typic differences. Furthermore, we pre-
dicted that GADA could detect most
cases of autoimmune diabetes.
RESEARCH DESIGN AND
METHODSdThe study design is
cross-sectional and includes adult-onset
diabetic patients, recruited between 2004
and 2007, from nine European countries:
Finland, Odense (Denmark), Vienna
(Austria), Belfast (Northern Ireland),
D€usseldorf (Germany), London (U.K.),
Lyon (France), Rome (Italy), and Barcelona
(Spain). Each center is involved in Action
LADA, a European Union–funded multi-
center European study with the aim of
identifying risk factors for adult-onset au-
toimmune diabetes (www.actionlada.
org). All centers recruited patients (aged
30–70 years, with primary diabetes, and
diagnosed within the past 5 years). Four
recruited from a community or primary
care setting (Helsinki, D€usseldorf, Rome,
and Odense). The remaining ﬁve centers
(Vienna, London, Belfast, Rome, Barce-
lona, and Lyon) recruited patients in a
hospital setting.
Patients were designated with diabe-
tes according to standard criteria, and
LADA was deﬁned as follows: patients
1) aged 30–70 years, 2) with diabetes-
associated autoantibodies, and 3) who
did not require insulin treatment for at
least 6 months postdiagnosis (12). Type
1 autoimmune diabetic patients were de-
ﬁned as case subjects with diabetes and
with diabetes-associated autoantibodies
in whom insulin was started at diagnosis
or within 1 month of diagnosis. Inclusion
criteria for all patients were that patients
have diabetes (with at least two recorded
fasting blood glucose measurements $7
mmol/L) (12), that time from diagnosis
was,5 years for all patients, and that pa-
tients were aged 30–70 years at the time of
recruitment. Exclusion criteria were insuf-
ﬁcient dataset, current pregnancy, renal
disease with raised creatinine or protein-
uria, or acute illness at the time of testing.
Data on medication and risk factors were
registered by the attending physician
based upon the medical ﬁles. Serum and
plasma samples were collected according
to standard procedures and stored at
2208C.
Waist and hip circumferences were
measured in a standardized procedure,
and blood pressure was recorded locally
for each subject. Blood pressure was
measured at least twice in the sitting
positions. Lipids and lipoproteins (serum
total and HDL cholesterol and triglycer-
ides) were determined by standardized
assays at each center.
All patients were tested in a central
laboratory (London) for serum GADA,
IA-2A, and ZnT8A using established ra-
dioimmunoprecipitation assays (13,14).
Positive results were duplicated, reducing
false positives to ,0.2%. In the 2003 Di-
abetes Antibody Standardization Program
(DASP 2003) (London), assay character-
istics were GADA sensitivity 72%, speci-
ﬁcity 95%, and IA-2A sensitivity 68%,
speciﬁcity 98% (15). In the latest DASP
program (DASP 2010), GADA sensitivity
was 90% and speciﬁcity 93%, IA-2A sen-
sitivity 68% and speciﬁcity 95%, and
ZnT8A sensitivity 60% and speciﬁcity
88% (M.I.H. and R.D.L., unpublished
data). The pJH4z1 probe for ZnT8A was
provided by Dr. J. Hutton (University of
Colorado, Denver, CO) and is a synthetic
molecule that combines cytoplasmic
ZnT8 COOH-terminal domains with an
immunoglobulin Cg3 hinge sequence
in a single-chain construct. It accounts
for a ZnT8 dimer containing the protein
epitopes 325Trp and 325Arg.
Each assay included serially diluted
sera from a prediabetic individual; these
in-house standards were diluted to an end
point. A separate positive serum sample
(equivalent to the World Health Organi-
zation [WHO] standard of 250 WHO
units) was used as an in-house control to
standardize each assay for unit calcula-
tion. The cutoff for positivity was selected
arbitrarily based on the end point of the
standard curve and further conﬁrmed
with Quantile-Quantile (Q-Q) probabil-
ity plots.
Statistical analysis
Data are presented, where appropriate, as
means SD, interquartile range, or odds
ratios (ORs) (95% CI). The differences
between groups were tested with x2 test
or Fisher exact test when appropriate. A
logistic regression analysis was performed
to evaluate confounding by covariables,
with adjustment for sex, age of onset, dis-
ease duration, and ethnicity to calculate
ORs. All analyses were performed using
SPSS statistical software for Windows.
AP value,0.05was considered statistically
signiﬁcant. Q-Q probability plots were
used to analyze the distribution of auto-
antibody measurements for normality.
Observed antibody values were plotted
along the horizontal axis against expected
normal values under normality on the
vertical axis using Blom proportion esti-
mation formula. The study protocol is in
accordance with the Declaration of Hel-
sinki and was approved by local ethics
committees in each study area. Informed
written consent was obtained from all
subjects before blood sampling. The
study was approved by the U.K. National
Research Ethics Committee (reference no.
P/02/240).
RESULTS
Diabetes autoantibody prevalence
and demographics
A total of 6,810 patients were screened for
diabetes-associated autoantibodies from
the samples received from the Action
LADA cohort. Of these, 654 subjects
were misclassiﬁed, owing to inappropri-
ate age or disease duration, and were
excluded. Of 6,156 subjects fulﬁlling the
inclusion criteria, 84.6% were Caucasian,
2.5% Asian, 1.2% African, 4.5% of the
Middle East, and 7.2% of other origins.
Overall mean (SD) age was 54.4 (9.6)
years, mean duration of diabetes was 2.2
(1.6) years, and 58.5% were male. Of
these 6,156 patients, 598 (9.7%) were
positive for at least one autoantibody
(Table 1). Of these, 68.6% were positive
for GADA only, 5.0% positive for IA-2A
only, and 2.3% positive for ZnT8A only
(Fig. 1). At least two autoantibody types
were found in 144 (24.1%) patients. The
determination of IA-2A and ZnT8A, in
addition to GADA, modestly improved
the recognition of autoimmune diabetes
from 8.8 to 9.7% of the total study group.
Within the entire cohort of patients with
autoimmune diabetes, 541 of 598
(90.5%) were positive for GADA.
The demographics of the autoanti-
body-positive and -negative patients are
shown in Table 1. GADA-positive pa-
tients in hospital-based clinics (10.0%)
were more prevalent than among the
community-based patients (7.8%) (P ,
0.0001) (Supplementary Table 1). Auto-
antibody-positive patients compared
with autoantibody-negative patients
had a signiﬁcantly lower mean age of on-
set (P , 0.001) (Table 1). Analysis of BMI
was corrected for age of onset, sex, and du-
ration of disease, and other analyses were
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corrected for age of onset, sex, duration of
disease, and BMI.Of autoantibody-positive
compared with autoantibody-negative pa-
tients after this correction, mean age, age
of onset, BMI, waist-to-hip ratio (WHR),
waist circumference, and systolic blood
pressure were signiﬁcantly lower (P ,
0.001), while HDL cholesterol was higher
(P, 0.001) (Table 1). No differences were
seen in LDL cholesterol values (Table 1).
More autoantibody-positive patients
were receiving insulin at the time of
examination (49.5% compared with
13.2% autoantibody-negative patients;
P , 0.001); the proportion was similar
in hospital-based and community-based
clinics (45.5 and 51.4%, respectively)
(Supplementary Table 1).
Diabetes phenotype by number of
autoantibodies
Patients positive for at least two autoanti-
bodies compared with those positive for a
single antibody did not show relevant
differences in any demographic or clinical
parameters (data not shown). Moreover,
patients with an autoantibody other than
GADA or with low-titer GADA were
leaner and more likely to be insulin
treated than autoantibody-negative pa-
tients (Supplementary Table 2 and Sup-
plementary Table 3).
Diabetes phenotypes by GADA titer
To further deﬁne autoantibody positivity,
for autoantibody titers on the whole co-
hort we used the Q-Q plot analysis, and a
laboratory cutoff set at 70 WHO units
from the standard curves was conﬁrmed,
with a further inﬂection at 200 WHO
units indicating high-titer GADA (Sup-
plementary Fig. 1). Patients with high-
titer GADA (n = 403), in contrast to
low-titer GADA (n = 138), were more
likely to be female and younger, have
lower BMI (P, 0.01 for all comparisons),
and lower serum triglycerides (P ,
0.001), andmore often be on insulin treat-
ment (54.6 vs. 39.7%; P = 0.005) (Table
2). Compared with GADA-negative pa-
tients, high–GADA titer patients had
lower waist circumference and WHR as
well as higher HDL cholesterol, and more
patients were insulin treated (P, 0.001 for
all comparisons) (Tables 1 and 2). Com-
pared with GADA-negative patients, the
low–GADA titer group also had lower
waist circumference, WHR, and BMI
(P , 0.01 for all comparisons), as well as
higher LDL cholesterol (P = 0.02), and
more patients were insulin treated (P ,
0.001) (Supplementary Table 3). Among
all GADA-positive patients, GADA titer
was directly correlated with age at diagno-
sis (r = 0.129, P = 0.010) and inversely
correlated with WHR (r = 20.103, P =
0.047) but not BMI (r =20.054, P = 0.24).
Comparative features of adult-onset
type 1 diabetes and LADA
Of 598 patients positive for at least one
autoantibody (GADA, IA-2A, or ZnT8A),
279 were on insulin; of these 279 insulin-
treated autoantibody-positive patients,
Figure 1dVenn diagram of numbers of patients with GADA, IA-2A, or ZnT8A; n = 598 of 6,156
(9.8%). Of the autoantibody-positive samples, GADA was identiﬁed in 90% of the samples when
an autoantibody was detected, with IA-2A and ZnT8A accounting for the remaining 10% of the
autoantibodies detected. GADA, n = 541 (8.8%); IA-2A, n = 144 (2.3%); and ZnT8A, n = 110 (1.8%).
Table 1dFeatures of any autoantibody-positive (GADA, IA-2A, or ZnT8A) versus
autoantibody-negative patients
Autoantibody positive Autoantibody negative P
Cases 598 5,558
Females, n (%)* 299 (50.0) 2,260 (40.7)
,0.001
Males, n (%) 294 (49.0) 3,298 (59.3)
Age (years) 49.6 (10.7) 54.9 (9.4) ,0.001
Age at onset (years) 47.4 (11.7) 52.5 (10.6) ,0.001
Duration of disease (years) 2.2 (1.6) 2.3 (1.6) .0.50
BMI (kg/m2) 27.2 (6.2) 30.9 (6.5) ,0.001
Subjects on insulin 279/564 (49.5) 728/5,508 (13.2) ,0.001
Time to insulin (years) 0.61 (1.03) 0.87 (1.4) 0.180
WHR 0.90 (0.1) 0.95 (0.09) ,0.001
Waist circumference (cm) 93.7 (16.1) 103.8 (14.6) ,0.001
HDL cholesterol (mmol/L) 1.44 (0.4) 1.29 (0. 39) ,0.001
LDL cholesterol (mmol/L) 2.05 (0.95) 1.60 (0.82) .0.50
Systolic BP (mmHg) 116.6 (29.1) 122 (31.0) ,0.001
TGL (mmol/L) 1.5 (1.4) 1.97 (1.5) ,0.001
Data are n,means (SD), or n/n (%) unless otherwise indicated.More autoantibody-positive patientswere receiving
insulin (49.5 vs. 13.2% autoantibody-negative patients; P, 0.001), younger (49.6 vs. 54.9 years old), and leaner
(27.2 vs. 30.9 kg/m2). BP, blood pressure; TGL, triglyceride. *Information for sex was missing in ﬁve auto-
antibody cases.
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information on precise time to insulin
therapy was available for 203, of whom
114 (56.2%) were designated as type 1
diabetic (started insulin at diagnosis and
all autoantibody positive), 65 (32.0%)
were classiﬁed as LADA (free of insulin
for .6 months from diagnosis and auto-
antibody positive), and 24 (11.8%) were
intermediate (started insulin within 6
months but after 1 month from diagnosis
and autoantibody positive).
LADA was more prevalent than clas-
sic autoimmune type 1 diabetes (OR 3.3).
Of autoantibody-positive patients, those
classiﬁed as type 1 diabetic compared
with LADA were younger and had a lower
age of onset, BMI, waist circumference,
andWHR (P, 0.001 for all comparisons)
but higher LDL cholesterol (P = 0.013),
whereas the number of patients with high
GADA titer did not differ between the
groups (80 vs. 79%) (Table 3).
CONCLUSIONSdThese observa-
tions show that adult-onset autoimmune
diabetes is not rare, as it was reported in
9.7% of this large cohort of adult-onset
diabetic patients diagnosed between 30
and 70 years of age attending primary and
secondary care European centers. Similar
studies have been much smaller with
marked selection bias, usually ascer-
taining only patients with non–insulin-
requiring diabetes (2–9). Nevertheless,
several of these studies also found that
~10% (range 5–15) of patients with adult-
onset diabetes have diabetes-associated
autoantibodies, notably GADA (2–9).
This present study is the largest to date
and beneﬁts from an analysis of all case
subjects attending these clinics, irrespective
of clinical features, as well as screening for
three major diabetes-associated autoanti-
bodies. Insulin autoantibodies, a feature
of childhood-onset diabetes, were not in-
cluded in our screening program, as we
were studying adults. The proportion of
case subjects classiﬁed with type 1 diabetes
is probably exaggerated, as clinicians who
had access to a local GADA assay result are
known to start insulin if the patient is
GADA positive (16). GADA were by far
the most prevalent diabetes-associated au-
toantibodies, with only a small additional
fraction of patients having other autoanti-
bodies. Thus, the projected shortfall of
ascertainment of adult-onset autoimmune
diabetes using GADA alone would be
small.
We show for the ﬁrst time that in
adult-onset diabetes, LADA is more fre-
quent than adult-onset autoimmune type
1 diabetes, but the two together do not
account for all cases of adult-onset auto-
immune diabetes, as some patients prog-
ress to insulin therapy between diagnosis
and 6 months postdiagnosis. Other stud-
ies, unlike this present analysis, failed to
eliminate the potential error resulting
from limited autoantibody speciﬁcity,
which we did by testing for all autoanti-
bodies twice to limit false positive results.
A potential bias in our study is the use of
hospital-based clinics in ﬁve of nine set-
tings, since patients with autoimmune
diabetes are more likely to be ascertained
in such clinics given their greater risk of
insulin treatment. Such a bias would
increase the relative proportion of cases
with autoantibodies and, speciﬁcally, the
proportion with type 1 diabetes com-
pared with LADAda bias evident for the
former but not the latter. That former bias
would not inﬂuence the characteristics of
autoantibody-positive versus autoantibody-
negative patients butmight further exagger-
ate the number of apparent cases of type 1
diabetes (16,17). The inclusion of patients
up to 4 years postdiagnosis might have led
to an underestimation of LADA cases be-
cause autoantibodies might become nega-
tive with time. Variation in ascertainment
through hospital-based or primary care–
based clinics around Europe precludes
analysis of differential frequencies of auto-
immune diabetes within Europe. Despite
these potential biases, there was a striking
excess of LADA compared with type 1 di-
abetes, implying that the typical presenta-
tion of adult-onset autoimmune diabetes
is as non–insulin-requiring diabetes, with
neither LADA nor type 1 diabetes, as de-
ﬁned, capturing all adult-onset autoim-
mune diabetes cases.
Patients with autoimmune diabetes in
this large cohort, compared with the re-
maining autoantibody-negative diabetic
patients, tended to more often be female,
younger at diagnosis, leaner, and subse-
quently more likely to be on insulin
treatment with metabolic changes includ-
ing higher HDL cholesterol and lower
triglycerides. These differences were
noted irrespective of the number of au-
toantibodies or presence or absence of
GADAs. Importantly, patients with auto-
antibodies other than GADA were also
leaner and more likely to be on insulin
treatment, consistent with them having a
disease process similar to that of the
GADA-positive patients. Among patients
with autoimmune diabetes, those with
type 1 diabetes, compared with the re-
mainder, also tended to be female, youn-
ger at diagnosis, leaner, and by deﬁnition,
on insulin treatment, with lower trigly-
cerides. Moreover, there was a striking
male excess in autoantibody-negative
type 2 diabetes cases, which was less ap-
parent here in adult-onset autoimmune
type 1 diabetes cases (51.8% male) but
still in line with the known male excess in
that group (18). Apart from detection of
diabetes-associated autoantibodies, there
were no categorical features that could
clinically distinguish adult-onset autoim-
mune diabetes from type 2 diabetes. We
identiﬁed at least two modes within the
GADA-positive patientsdone mode
with a cutoff of 70 WHO IU (low GADA
titer) and another at 200 WHO IU (high
GADA titer)dthough it should be noted
Table 2dFeatures of GADA high- versus GADA low-titer patients
GADA high GADA low P
Cases 403 138
Females, n (%) 220 (54.4) 59 (42.8)
Males, n (%) 180 (44.6) 78 (56.5) 0.02
Age (years) 49.3 (10.7) 50.2 (10.9) 0.09
Age at onset (years) 47.0 (14.0) 47.6 (10.8) 0.08
Duration of disease (years) 2.14 (1.6) 2.46 (1.7) 0.07
BMI (kg/m2) 26.7 (6.1) 28.5 (6.6) 0.008
Subjects on insulin 207/379 (54.6) 52/131 (39.7) 0.005
Time to insulin (years) 0.67 (1.0) 0.86 (1.4) 0.81
WHR 0.90 (0.1) 0.89 (0.1) 0.10
Waist circumference (cm) 92.0 (15.7) 96.7 (16.6) 0.013
HDL cholesterol (mmol/L) 1.49 (0.5) 1.44 (0.5) 0.6
LDL cholesterol (mmol/L) 2.36 (0.98) 2.16 (1.08) 0.33
Systolic BP (mmHg) 116.3 (28.8) 116.0 (31.1) 0.96
TGL (mmol/L) 1.23 (0.9) 1.81 (1.7) 0.002
Data are n, means (SD), or n/n (%) unless otherwise indicated. BP, blood pressure; TGL, triglyceride.
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that it may not be possible to relate our
cutoff values to other GADA assay levels.
Patients with high-titer compared with
low-titer GADAs were more likely to be
female, younger at onset, leaner, and on
insulin treatment, with lower HDL cho-
lesterol and higher triglycerides; in these
features, they resemble patients with type
1 diabetes. However, each form of auto-
immune diabetes could be found across
the range of GADA titers, though type 1
diabetic patients tended to have high
titers and LADA patients tended to have
low titers. Moreover, patients with low
GADA titer, compared with those who
were GADA negative, were also younger
at diagnosis and leaner with higher HDL
cholesterol, and a higher proportion was
treated with insulin. Thus, there is a gra-
dation of clinical and biochemical fea-
tures in patients, in which GADA titer
is a continuous variable, ranging from
high through low titer to GADA negativity,
without any clear distinction apart from
the presence or absence of GADA. Other
smaller studies have shown that high-
titer GADA-positive patients had a ten-
dency to greater genetic (HLA) disease
associations compared with low–GADA
titer patients and that these genetic asso-
ciations for autoimmune diabetes are
broadly similar even over awide age range,
as are components of the metabolic syn-
drome (5,19,20).
As a result, we recommend that type 1
diabetes and LADA be viewed as part of a
broad clinical spectrum that more truly
represents autoimmune diabetes. The
most prevalent form of diabetes is adult-
onset type 2 diabetes, which affects ~4–
7% of the adult European population.
Childhood-onset type 1 diabetes, on the
other hand, affects only some 0.25% of
European children and adolescents,
though a lifetime disease-risk analysis
suggested that up to 1% develop classic
type 1 diabetes, with a proportion doing
so after age 30 years (21). Since we now
show that nearly 10% of adult-onset di-
abetic patients have autoimmune di-
abetes, it follows that adult-onset
autoimmune diabetes is probably more
prevalent than childhood-onset type 1 di-
abetes, while in adult-onset autoimmune
diabetes, LADA is more prevalent than
classic type 1 diabetes (OR 3.3). Clini-
cally, knowledge that adult-onset diabetic
patients have GADA should alert physi-
cians to the increased likelihood of more
rapid progression to insulin therapy; i.e.,
there is value in measuring GADA in all
adult-onset diabetes cases because a sig-
niﬁcant proportion of them with GADA,
unidentiﬁable by clinical phenotype, po-
tentially have a different therapeutic tra-
jectory than in classic type 2 diabetes. In
summary, this present study now shows
that the majority of adult-onset autoim-
mune diabetic patients are non–insulin
requiring at diagnosis and can be identi-
ﬁed through GADA screening. In the ten-
dency to be adult onset, with variable
destruction of the target organ, leading
to a broad clinical spectrum, autoimmune
diabetes can now be seen to resemble
other autoimmune diseases.
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